Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10484777 | Value in Health | 2015 | 8 Pages |
Abstract
In the overall trial population, LDX was associated with a lower rate of treatment failure compared with OROS-MPH in patients with ADHD. A more pronounced benefit of LDX over OROS-MPH was observed among subpopulations with a higher predicted risk of failing OROS-MPH. The present study showed the feasibility of individualizing treatment selection. Future research is needed to prospectively verify these results.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Juliana PharmD, MS, Hongbo PhD, David BS, Xiaopeng MS, James PhD, Jipan PhD, M. Haim PhD,